Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX23.186,49-0,53 %

Gold3.365,90-0,09 %

Öl (Brent)77,58+1,68 %

Dow Jones41.943,01-0,51 %

US Tech 10021.571,70-0,64 %

EUR/USD1,14739-0,09 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Aktie

ISIN: NL0010832176 WKN: A11602 SYM: 1AE Land Flagge NL

Niederlande

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

468,70

EUR

-0,02 %

-0,10 EUR

Letzter Kurs 11:07:37 Tradegate

argenx Aktie kaufen

Geldkurs

14:17:45

472,20

EUR

21 STK

Briefkurs

14:17:45

472,60

EUR

21 STK

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease 11.06.25 · globenewswire · argenx
28 Top-Picks: Jefferies’ Aktien-Favoriten für den Sommer 10.06.25 · wallstreetONLINE Redaktion · Caterpillar
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference 03.06.25 · globenewswire · argenx
argenx Announces Results of Annual General Meeting of Shareholders 28.05.25 · globenewswire · argenx
argenx Reports First Quarter 2025 Financial Results and Provides Business Update 08.05.25 · globenewswire · argenx
argenx to Present at BofA Securities 2025 Health Care Conference 06.05.25 · globenewswire · argenx
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 01.05.25 · globenewswire · argenx
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 28.04.25 · globenewswire · argenx
argenx Announces Annual General Meeting of Shareholders on May 27, 2025 11.04.25 · globenewswire · argenx
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy 10.04.25 · globenewswire · argenx
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP 08.04.25 · globenewswire · argenx
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting 07.03.25 · globenewswire · argenx

1
2
…
3

Meistgelesen

30 Tage
12 Monate

28 Top-Picks: Jefferies’ Aktien-Favoriten für den Sommer 10312 Leser
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference 112 Leser
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept ... 108 Leser
argenx Announces Results of Annual General Meeting of Shareholders 104 Leser

28 Top-Picks: Jefferies’ Aktien-Favoriten für den Sommer 10312 Leser
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating ... 416 Leser
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 ... 364 Leser
Halozyme nimmt Vorschlag über Zusammenschluss mit Evotec aufgrund fehlender ... 332 Leser
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic ... 328 Leser
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies 272 Leser
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update 216 Leser
argenx to Present at Upcoming Investor Conferences 208 Leser
Halozyme bestätigt Vorschlag des Zusammenschlusses mit Evotec für 11,00 EUR pro Aktie im ... 180 Leser
argenx Highlights 2025 Strategic Priorities 176 Leser